权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Functional and molecular basis of ineffective erythropoiesis in SF3B1-mutant myelodysplastic syndromes

SF3B1 突变型骨髓增生异常综合征无效红细胞生成的功能和分子基础

基本信息

批准号：
10662579
负责人：
Robert K Bradley
金额：
$ 63.37万
依托单位：
FRED HUTCHINSON CANCER CENTER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-01 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10662579
关键词：
Affect Biological Models Biology Blood Blood typing procedure Cell Line Cells Characteristics Classification Clonal Expansion Defect Development Disease Disease Progression Disease model Dysmyelopoietic Syndromes Erythroid Erythropoiesis Event Face Genes Genetic Genotype Health Hematological Disease Hematopoiesis Hematopoietic stem cells Heme High Prevalence Impairment Incidence Iron Knock-out Lesion Link Maps Measures Mediating Messenger RNA Mitochondria Modeling Molecular Morbidity - disease rate Mutant Strains Mice Mutate Mutation Pathogenicity Patients Phenotype Physicians Privatization Process Production Proteins Protoporphyrinogen oxidase Public Health RNA RNA Splicing Reaction Scientist Sideroblast Somatic Mutation Spliced Genes Spliceosomes Therapeutic Therapeutically Targetable Transcript Transfusion Translations Treatment Efficacy Untranslated RNA Work cohort disease phenotype erythroid differentiation experimental study functional genomics genome-wide hematopoietic differentiation heme biosynthesis induced pluripotent stem cell mRNA Translation mortality mutant novel novel strategies novel therapeutics predictive modeling stem cell model stem cells targeted treatment therapeutic evaluation transcriptome

项目摘要

SUMMARY The majority of patients with myelodysplastic syndromes (MDS), a heterogeneous group of blood disorders characterized by ineffective and clonal hematopoiesis, carry a somatic mutation affecting an RNA splicing factor. The most commonly mutated splicing factor is SF3B1, a core component of the spliceosome that is preferentially mutated in MDS with ring sideroblasts (MDS-RS). Although SF3B1 mutations are among the most common genetic lesions in MDS, they are nonetheless relatively poorly understood. Our incomplete understanding of SF3B1 mutations is due in part to the absence of a model system that recapitulates hallmark disease phenotypes, including ring sideroblast formation and ineffective erythropoiesis. As a consequence, it is unclear how SF3B1 mutations alter RNA splicing mechanisms, which specific mis-spliced genes drive hallmark disease phenotypes, and whether SF3B1-mutant cells can be killed by targeted therapies. Here, we propose to elucidate the functional basis as well as mechanistic and phenotypic consequences of SF3B1 mutations in MDS-RS. Our team consists of a stem cell biologist with expertise in hematologic disease modeling (Doulatov), a basic scientist with expertise in RNA splicing and functional genomics (Bradley), and a physician-scientist with expertise in erythropoiesis and heme biology (Abkowitz). In preliminary studies, we generated MDS-RS patient-derived induced pluripotent stem cells (iPSCs) that recapitulate hallmark disease phenotypes during erythroid differentiation, identified specific mis-spliced genes that contribute to ineffective erythropoiesis, and performed functional genomic screens to identify molecular vulnerabilities of SF3B1-mutant cells. We propose to build on those preliminary studies as follows: Aim 1, Define the molecular consequences of SF3B1 mutations for mRNA splicing, stability, and translation; Aim 2, Determine the functional basis of ring sideroblast formation and ineffective erythropoiesis in SF3B1-mutant MDS-RS; Aim 3, Identify therapeutic opportunities for treating MDS-RS with SF3B1 mutations. The significance of these studies is that they will elucidate the mechanistic and functional consequences of SF3B1 mutations in MDS-RS. The health relatedness is that the proposed work may identify new opportunities for treating MDS by specifically targeting SF3B1-mutant cells. As the incidence of MDS is rising and patients with SF3B1-mutant MDS-RS face life-long transfusion burdens and associated morbidity and mortality, there is a public health need to develop new therapies for this disorder.

总结骨髓增生异常综合征（MDS）是一组异质性血液疾病，以无效和克隆造血为特征，携带影响RNA剪接的体细胞突变因子最常见的突变剪接因子是SF 3B 1，它是剪接体的核心成分，在具有环形铁粒幼细胞的MDS（MDS-RS）中优先突变。虽然SF 3B 1突变是尽管MDS是MDS中最常见的遗传性病变，但对其了解相对较少。我们的不完整对SF 3B 1突变的理解部分是由于缺乏一个模型系统，疾病表型，包括环形铁粒幼细胞形成和无效的红细胞生成。因此，目前尚不清楚SF 3B 1突变如何改变RNA剪接机制，哪些特定的错误剪接基因驱动标志物疾病表型，以及SF 3B 1突变细胞是否可以被靶向治疗杀死。在这里，我们建议阐明的功能基础，以及机制和表型的后果， MDS-RS中的SF 3B 1突变。我们的团队由一位具有血液病专业知识的干细胞生物学家组成建模（Doulatov），具有RNA剪接和功能基因组学专业知识的基础科学家（布拉德利），以及具有红细胞生成和血红素生物学专长的医生-科学家（Abkowitz）。在初步研究中，我们产生的MDS-RS患者来源的诱导多能干细胞（iPSC），在红细胞分化过程中的表型，确定了特定的错误剪接基因，有助于无效的红细胞生成，并进行功能基因组筛选，以确定SF 3B 1突变体的分子脆弱性，细胞我们建议在这些初步研究的基础上进行以下工作：目标1，确定分子结果 SF 3B 1突变对mRNA剪接、稳定性和翻译的影响;目的2，确定环的功能基础 SF 3B 1突变型MDS-RS中铁粒幼细胞形成和无效红细胞生成;目的3，治疗具有SF 3B 1突变的MDS-RS的机会。这些研究的意义在于，阐明MDS-RS中SF 3B 1突变的机制和功能后果。健康相关性是，拟议的工作可能会确定新的机会，治疗MDS的具体目标， SF 3B 1突变细胞。随着MDS发病率的上升和SF 3B 1突变型MDS-RS患者面临终身输血负担和相关的发病率和死亡率，公共卫生需要开发新的治疗这种疾病。

项目成果

期刊论文数量（3）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Induced pluripotent stem cell models of myeloid malignancies and clonal evolution.

DOI：
10.1016/j.scr.2021.102195
发表时间：
2021-04
期刊：
STEM CELL RESEARCH
影响因子：
1.2
作者：
Reilly, Andreea;Doulatov, Sergei
通讯作者：
Doulatov, Sergei

Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells.

DOI：
10.1097/moh.0000000000000620
发表时间：
2021-01
期刊：
Current opinion in hematology
影响因子：
3.2
作者：
Doulatov S;Papapetrou EP
通讯作者：
Papapetrou EP

Induced pluripotent stem cell line (SDQLCHi041-A) from a male patient with mucopolysaccharidosis type IIIB.

来自 IIIB 型粘多糖贮积症男性患者的诱导多能干细胞系 (SDQLCHi041-A)。

DOI：
10.1016/j.scr.2021.102212
发表时间：
2021
期刊：
Stem cell research
影响因子：
1.2
作者：
Guan,Jingyun;Tian,Guangyan;Dong,Rui;Zhang,Haiyan;Yang,Xiaomeng;Li,Yue;Gai,Zhongtao;Liu,Yi
通讯作者：
Liu,Yi